Plaintiffs Seek Appointment of Leadership in Ozempic MDL

PHILADELPHIA — Plaintiffs in the MDL for cases alleging injuries caused by glucagon-like peptide-1 receptor agonists (GLP-1RAs) have filed an amended motion for appointment of leadership, arguing the “proposed co-lead counsel have already undertaken significant efforts to advance this litigation over the past seven months, and readily satisfy all potentially applicable criteria for appointment.”

Proposed co-lead counsel are Parvin Aminolroaya of Seeger Weiss, LLP, Sarah Ruane of Wagstaff & Cartmell LLP, Jonathan D. Orent of Motley Rice, LLC and Paul Pennock of Morgan & Morgan P.A. Proposed liaison counsel are Roberta Liebenbeg of Fine Kaplan & Black R.P.C. and Nina …